本文關(guān)鍵詞：探索預(yù)測(cè)索拉菲尼治療晚期原發(fā)性肝細(xì)胞癌療效的分子標(biāo)志物的研究，由筆耕文化傳播整理發(fā)布。

探索預(yù)測(cè)索拉菲尼治療晚期原發(fā)性肝細(xì)胞癌療效的分子標(biāo)志物的研究 趙 鵬1，陳 東2，，陳 偉2，殷曉煜2， 梁力建2 （536003 貴州 遵義，遵義醫(yī)學(xué)院附屬第一醫(yī)院肝膽外科1； 510080廣州，中山大學(xué)附屬第一醫(yī)院肝膽外科2） [摘要] 目的 探索可能預(yù)測(cè)索拉菲尼治療晚期原發(fā)性肝細(xì)胞癌 epatocellular carcinoma,HCC 療效的分子標(biāo)志物。方法 回顧性分析應(yīng)用索拉菲尼治療的54例晚期HCC患者臨床資料，將索拉菲尼治療前病理組織切片分別以抗體VEGFR、pERK、pS6K、PTEN進(jìn)行免疫組組織化學(xué)染色（IHC），根據(jù)各抗體染色結(jié)果的不同分為高表達(dá)組和低表達(dá)組，結(jié)合索拉菲尼治療后的疾病進(jìn)展時(shí)間（time to progression, TTP） VEGFR、pERK高表達(dá)組較低表達(dá)組的TTP明顯延長(zhǎng)（P＜0.05），PS6K兩組之間的TTP無(wú)顯著差異（P＞0.05）PTEN幾乎無(wú)陽(yáng)性表達(dá)To investigate the candidate molecular markers for predicting the efficacy of sorafenib in treating with advanced HCC Zhao Peng1, Chen Dong 2, Chen Wei2, 2Yin Xiaoyu, 2Liang Lijian 1Department of Hepatobiliary Surgery, the First Affiliated Hospital of ZunYi Medical College, ZunYi, 536003, China. 2Department of hepatobiliary surgery, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou,510080, China. Corresponding author LIANG Li-jian ,E-mail:[email protected] [Abstract] Objective To investigate the candidate molecular markers for predicting the efficacy of sorafenib in treating with advanced HCC.Methods In this retrospective study , 54 advanced HCC patients were given sorafenib 400mg twice a day and the time to progression TTP were recorded. Sections cut from paraffin-embedded liver tumor biopsies from the 54 patients which were obtained before sorafenib treatment were analyzed with immunohistochemistry staining IHC using rabbit polyclonal antibodies for phosphorylated extracellular signal regulated kinase p

  本文關(guān)鍵詞：探索預(yù)測(cè)索拉菲尼治療晚期原發(fā)性肝細(xì)胞癌療效的分子標(biāo)志物的研究，由筆耕文化傳播整理發(fā)布。